Concepedia

Author

Hugo Ford

Cambridge University Hospitals NHS Foundation Trust

Also Known As

H E R Ford, H Ford, H. E. R. Ford, H. Ford, H.E.R. Ford, Hugo E Ford, Hugo E R Ford, Hugo E. Ford, Hugo E. R. Ford, Hugo E.R. Ford

54

Publications

2.1K

Citations

20

H-Index

26

Concepts

All Affiliations

Cambridge University Hospitals NHS Foundation TrustRoyal Marsden HospitalRoyal Marsden NHS Foundation TrustAddenbrooke's HospitalUniversity College London
HF

About

Hugo Ford is an author at Cambridge University Hospitals NHS Foundation Trust specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

573

2

Health Sciences

2

2

49

3

Gastroenterology

2

2

32

4

Allergy

1

1

35

5

Immunology

1

1

35

Hugo Ford

×

22

Publications

2K

Citations

18

H-Index

YearCitations

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater,

The Lancet Oncology

2013

597

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal,

Journal of Clinical Oncology

2008

217

The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer

Ian Chau, Mark Allen, David Cunningham,

Journal of Clinical Oncology

2004

156

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill,

˜The œLancet. Gastroenterology & hepatology

2023

155

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma

Fergus Noble, Megan Lloyd, Richard Turkington,

British journal of surgery

2017

107

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

David Farrugia, Hugo Ford, David Cunningham,

PubMed

2003

63

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma

Eleni Andreopoulou, Paul J. Ross, Mary O’Brien,

Annals of Oncology

2004

42

Venous thromboembolism in oesophago-gastric carcinoma: Incidence of symptomatic and asymptomatic events following chemotherapy and surgery

Katie E. Rollins, Christopher J. Peters, Peter Safranek,

European Journal of Surgical Oncology

2011

39

Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

Hugo Ford, Fraser Mitchell, David Cunningham,

PubMed

2002

35

Page 1